¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"CD4:CD8 ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • CD4
    CD4
  • CD8
    CD8
  • arm ratio
    µÎÆÈºñ
  • axial ratio
    Ãàºñ
  • abortion ratio
    À¯»êºñ
  • age-dependency ratio
    ¿¬·ÉºÎ¾çºñ
  • air entrainment ratio
    °ø±âÀ¯ÀÔ·ü
  • air pollution ratio
    ´ë±â¿À¿°·ü
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î³úô¼ö¾×/Ç÷ûºñ
  • albumin-globulin ratio
    ¾ËºÎ¹Î±Û·ÎºÒ¸°ºñ
  • birth-death ratio
    Ãâ»ý»ç¸Áºñ
  • blood urea nitrogen/creatinine ratio
    Ç÷¾×¿ä¼ÒÁú¼Ò/Å©·¹¾ÆÆ¼´Ñºñ
  • body-weight ratio
    üÁß½ÅÀåºñ
  • breathing reserve ratio
    ȯ±â¿¹ºñºñ
  • common ratio
    °øºñ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ratio
    ºñ, À²
  • correlation ratio
    »ó°üºñ
  • inspiratory expiratory ratio
    µé¼û³¯¼ûºñÀ², ÈíÈ£±â´ëºñ
  • odds ratio
    ±³Â÷ºñ
  • scatter-maximum ratio
    ÃÖ´ë»ê¶õºñ
  • segregation ratio
    ºÐ¸®ºñ
  • sex ratio
    ¼ººñ
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
  • uptake ratio
    ¼·ÃëÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • A-G ratio
    (¢¡albumin-globulin ratio) ¾ËºÎ¹Î±Û·ÎºÒ¸°ºñ
  • abortion ratio
    À¯»êºñ
  • age-dependency ratio
    ¿¬·ÉºÎ¾çºñ
  • air entrainment ratio
    °ø±âÀ¯ÀÔ·ü
  • air pollution ratio
    ´ë±â¿À¿°·ü
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î³úô¼ö¾×Ç÷ûºñ
  • albumin-globulin ratio
    ¾ËºÎ¹Î±Û·ÎºÒ¸°ºñ
  • arm ratio
    µÎÆÈºñ
  • axial ratio
    Ãàºñ
  • benefit/risk ratio
    À¯ÀÍÀ¯ÇغñÀ²
  • birth-death ratio
    Ãâ»ý»ç¸Áºñ
  • blood urea nitrogen/creatinine ratio
    Ç÷¾×´¢¼ÒÁú¼ÒÅ©·¹¾ÆÆ¼´Ñºñ
  • body-weight ratio
    üÁß½ÅÀåºñ, ¸ö¹«°ÔŰºñ
  • breathing reserve ratio
    ȯ±â¿¹ºñºñ
  • caliber ratio
    Ç÷°ü°æºñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • CD4+ cell
    CD4+ ¼¼Æ÷
  • AC/A ratio->ratio of accommodative convergence to accommodation
    Á¶ÀýÆøÁÖºñ
  • A£¯G ratio=£¾albumin globulin ratio
    A£¯G ºñ.
  • U/S osmol ratio => urine/serum osmol ratio
    ¼Òº¯/Ç÷û ¿À½º¸ôºñ
  • DeRitis ratio
    µå¸®Æ¼½ººñÀ²
  • Donnan ratio
    µ·³­À²
  • G/N ratio
    G/Nºñ Æ÷µµ´ç°ú Áú¼ÒÀÇ ºñÀ² .
  • INR => International Normalized Ratio
    ±¹Á¦Á¤»óÈ­ºñÀ²
  • International Normalized Ratio
    ±¹Á¦Á¤»óÈ­ºñÀ²
  • International Normalized Ratio=INR
    ±¹Á¦Á¤»óÈ­ºñ
  • L/S ratio
    L/S ºñÀ²
  • OER [=oxygen enhancement ratio]
    »ê¼Ò°­È­À²
  • S-D ratio
    ¼öÃà±â-À̿ϱ⠺ñ (â¥õêÑ¢-ì¬èÐÑ¢ Ýï)
  • SNR (signal to noise ratio)
    ½ÅÈ£´ë ÀâÀ½ºñÀ²
  • V/Q => ventilation/perfusion ratio
    ȯ±â/°ü·ùºñ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dextrosenitrogen ratio =DN ratio
    Æ÷µµ´çÁú¼Òºñ.
  • air entrainment ratio
    °ø±âÀ¯ÀÔ·ü.
  • air pollution ratio
    ´ë±â¿À¿°·ü(ÊÙËô).
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î ³úô¼ö¾×/Ç÷û ºñ
  • albumin-globulin ratio =A£¯G r.
    ¾ËºÎ¹Î ±Û·ÎºÒ¸°ºñ.
  • albumin/globulin ratio
    ¾ËºÎ¹Î/±Û·ÎºÒ¸° ºñ
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • arm ratio
    µÎÆÈºñ(¡­Ýï).
  • axial ratio
    Ãàºñ(õîÝï)
  • benefit/risk ratio
    À¯ÀÍ/À¯ÇغñÀ².
  • birth-death ratio
    Ãâ»ý-»ç¸Áºñ(õóßæÞÝØÌÝï).
  • birth-death ratio
    Ãâ»ý-»ç¸Áºñ(̧Ë×Ë×ËÎËÓ).
  • blood urea nitrogen/creatinine ratio
    Ç÷¾×´¢¼ÒÁú¼Ò/Å©·¹¾ÆÆ¼´Ñ ºñ(À²)
  • body-weight ratio
    üÁß½ÅÀåºñ(ô÷ñìãóíþÝï).
  • breathing reserve ratio
    ȯ±â¿¹ºñºñ(¡­çãÝáÝï).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • absorption ratio
    Èí¼öÀ² (ýåâ¥ëÒ)
  • acceptor-control ratio
    ¼ö¿ëü Á¦¾îÀ² (â¥é»ô÷ ð¤åÙëÒ)
  • affinity ratio
    ģȭºñ(öÑûúÝï)
  • A/G ratio
    A/G ºñ (Ýï)
  • albumin/globulin ratio
    ¾ËºÎ¹Î/±Û·ÎºÒ¸° ºñ(Ýï)
  • asymmetry ratio
    ºÒ±Õµîºñ (ÝÕгÔõÝï)
  • A+T/G+C ratio
    A+T/G+C ºñ (Ýï)
  • base-pair ratio
    ¿°±â¦ ºñ(Ýï)
  • base ratio
    ¿°±âºñ(ç¤ÐñÝï)
  • channels ratio method
    ä³Î ºñÀ²¹ý(Ýï×ËÛö)
  • coding ratio
    ºÎÈ£ºñ(ݬûÜÝï)
  • dichroic ratio
    ÀÌ»öºñ(ì£ßäÝï)
  • disequilibrium ratio
    ºÒÆòÇü ºñÀ²(ÝÕøÁû¬Ýï×Ë)
  • dissymmetry ratio
    ºÒ¿ÏÀü´ëĪ ºñÀ²(ÝÕèÇîïÓßöàÝï×Ë)
  • distribution ratio
    "ºÐÆ÷À²(ÝÂøÖëÒ), (ÔÒ) partition coefficient"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cardiothoracic ratio
    ½ÉÈä(°û)ºñ, ½ÉÈä°è¼ö
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast to noise ratio
    ´ëÁ¶ÀâÀ½ºñ
  • depth to width ratio
    ±íÀÌÆøºñÀ²
  • gyromagnetic ratio
    ȸÀüÀÚ±âºñÀ²
  • heart lung ratio
    ½ÉÆó°è¼ö
  • magnetization transfer ratio [=MTR]
    ÀÚÈ­Àü´ÞºñÀ²
  • ratio
    ºñ
  • signal to noise ratio [=SNR]
    ½ÅÈ£´ëÀâÀ½ºñ
  • SNR [=signal to noise ratio]
    ½ÅÈ£´ëÀâÀ½ºñÀ²
  • uptake ratio
    ¼·ÃëÀ²
  • velocity ratio
    ¼Óµµºñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CD8 HIV suppressor cell count
ICL Idiopathic CD4 + T Lymphocytopenia
CD4 HIV helper cell count
ICL idiopathic CD4 T-cell lymphocytopenia; iris-clip lens; isocitrate lyase
AR absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CD4+ CD4 positive
h-CD4 human CD4
CTL CD8 T lymphocyte
SCD8 soluble CD8
ICL Idiopathic CD4 T lymphocytopenia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • CD4
    T4
    lym
  • air entrainment ratio
    °ø±â À¯ÀÔ·ü
  • benefit/risk ratio
    À¯ÀÍ/À¯ÇØ ºñÀ²
  • body-weight ratio
    üÁß ½ÅÀå ºñ
  • cardiothoracic ratio
    ½ÉÈäºñ, ½ÉÈä°û ºñ, ½ÉÈä °è¼ö
  • cell color ratio
    Ç÷±¸»ö¼Òºñ, ÀûÇ÷±¸ »ö¼Òºñ
  • child woman ratio
    ¸ð¾Æ ºñÀ²
  • crown-root ratio
    Ä¡°ü´ë Ä¡±Ùºñ
  • curative ratio
    Ä¡À¯À²
  • death ratio
    »ç¸Áºñ
    µ¿ÀǾî=
  • effective ratio
    À¯È¿À²
    ¾î´À ÇѰè±îÁö´Â ¾àÁ¦ ¿ë·®°ú À¯È¿À²Àº ºñ·ÊÇÑ´Ù. ÇѰè À̻󿡼­´Â ºÎÀÛ¿ëÀÌ ³ªÅ¸³­´Ù.
  • expansion ratio
    ÆØÃ¢ºñ
  • innervation ratio
    ½Å°æ Áö¹è ºñ
  • magnetization transfer ratio
    ÀÚÈ­ Àü´Þ ºñÀ²
  • mercuryalloy ratio
    ¼öÀº Çձݺñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
CD4:CD8 ratio The ratio of CD4 to CD8 cells. A common measure of immune system status that is around two in healthy individuals. The ratio of T-lymphocytes that express the CD4 antigen to those that express the CD8 antigen. This value is commonly assessed in the diagnosis and staging of diseases affecting the immune system including HIV infection.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
CD4/CD8 count The ratio of the number of helper-inducer T lymphocytes to cytotoxic-suppressor T lymphocytes, as measured by monoclonal antibodies to the CD4 surface antigen found on helper-inducer T-cells, and the CD8 surface antigen found on cytotoxic-suppressor T-cells. In healthy individuals, the H/S ratio ranges between 1.6 and 2.2.When the body mounts an immune response, as against a virus or a transplant, the ratio is almost always reduced because of a decrease in the number of circulating helper-inducer cells and an increase in suppressor cells. The CD4/CD8 count has been used to monitor for signs of organ rejection after transplants, and more recently has become a tool for assessing the relative condition of HIV patients. With the CD4 absolute count and the CD4 lymphocyte percentage, it provides a way of gauging the progression from HIV to AIDS.
(05 Mar 2000)
antigens, CD8 <immunology> Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. Cd8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in major histocompatibility complex class I-restricted interactions.
(12 Dec 1998)
CD8 <immunology> Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. Cd8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in major histocompatibility complex class I-restricted interactions.
(12 Dec 1998)
CD8 cell <immunology> One type of T-lymphocyte which bears the CD8 molecular marker on its surface. Some CD8 cells recognise and kill cancerous cells and those infected by intracellular pathogens (some bacteria, viruses and mycoplasma). These cells are called cytotoxic T-lymphocytes (see).
(09 Oct 1997)
CD8-positive T-lymphocytes A critical subpopulation of regulatory T-lymphocytes involved in MHC class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-lymphocytes, cytotoxic) and suppressor T-lymphocytes (T-lymphocytes, suppressor-effector).
(12 Dec 1998)
absolute CD4 count The number of helper T-lymphocytes in a cubic millimeter of blood. With HIV, the absolute CD4 count declines as the infection progresses. The absolute CD4 count is frequently used to monitor the extent of immune suppression in persons with HIV. Also called a T4 count.
(12 Dec 1998)
antigens, CD4 <immunology> 55-kD glycoproteins originally defined as differentiation antigens on T-lymphocytes, but also found on other cells including monocytes/macrophages. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MHC (major histocompatibility complex) class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. Cd4 antigens also serve as HIV receptors, binding directly to the envelope protein gp120 on HIV.
The protein structure on the surface of a human cell that allows HIV to attach, enter, and thus infect a cell. CD4 receptors are present on CD4 cells (helper T-cells), macrophages and dendritic cells, among others. Normally, CD4 acts as an accessory molecule, forming part of larger structures (such as the T-cell receptor) through which Tcells and other cells signal each other.
(12 Dec 1998)
CD4 <immunology> 55-kD glycoproteins originally defined as differentiation antigens on T-lymphocytes, but also found on other cells including monocytes/macrophages. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MHC (major histocompatibility complex) class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. Cd4 antigens also serve as HIV receptors, binding directly to the envelope protein gp120 on HIV.
The protein structure on the surface of a human cell that allows HIV to attach, enter, and thus infect a cell. CD4 receptors are present on CD4 cells (helper T-cells), macrophages and dendritic cells, among others. Normally, CD4 acts as an accessory molecule, forming part of larger structures (such as the T-cell receptor) through which Tcells and other cells signal each other.
(12 Dec 1998)
CD4 cell T helper cells which are targets for HIV infection.
(09 Oct 1997)
CD4 cell count The most commonly used surrogate marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. The normal range for CD4 cell counts is 500 to 1500 per cubic millimetre of blood. CD4 count should be rechecked at least every six to twelve months if CD4s are greater than 500/mm3. If the count is lower, testing every three months is advised.
(09 Oct 1997)
CD4 count, absolute The number of helper T-lymphocytes in a cubic millimeter of blood. With HIV, the absolute CD4 count declines as the infection progresses. The absolute CD4 count is frequently used to monitor the extent of immune suppression in persons with HIV. Also called a T4 count.
(12 Dec 1998)
CD4 immunoadhesins <immunology> Chimeric molecules resulting from the fusion of recombinant soluble CD4 to the fc portion of immunoglobulins. These have potential use in the therapy of aids since they possess both the gp120-binding and HIV-blocking properties of rCD4 as well as the long plasma half-life and fc receptor-binding functions of immunoglobulin.
(12 Dec 1998)
CD4 lymphocyte A specific type of lymphocyte, derived from the thymus gland, that plays an important role in cellular immunity. T4 lymphocytes (CD4 cells) are decreased (absolute counts less than 200) in patients with AIDS resulting in compromised immune function.
(27 Sep 1997)
CD4 lymphocyte count A count of the number of CD4-positive lymphocytes in the blood. Determination requires the use of a fluorescence-activated flow cytometer.
(12 Dec 1998)
CD4-positive T-lymphocytes A critical subpopulation of regulatory T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the t4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes, which includes both the helper-inducer (T-lymphocytes, helper-inducer) and suppressor-inducer (T-lymphocytes, suppressor-inducer) T-cells.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ratio
    ºñ
  • cash ratio
    (ÀºÇàÀÇ ÁöºÒ Áغñ±ÝÀÇ ÃÑ¿¹±Ý¿¡ ´ëÇÑ)Çö±Ý ºñÀ²
  • compression ratio
    (¿£ÁøÀÇ) ¾ÐÃàºñ
  • conversion ratio
    Àüȯ ºñÀ²(Çٺп­½Ã ÇϳªÀÇ ¿øÀÚ¿¡¼­ »ý±â´Â ¿øÀÚÀÇ ¼ö
  • cost performance (ratio)
    ºñ¿ë´ë ¼º´Éºñ
  • direct ratio
    (¼ö)Á¤ºñ;Á¤ºñ·Ê
  • elderly dependency ratio
    ³ë·ÉÀÚ(ÇÇ)ºÎ¾ç·ü
  • focal ratio
    =F-NUMBER
  • inverse ratio
    (¼ö)¹Ýºñ;¿ªºñ
  • mass ratio
    Áú·®ºñ (ÃßÁøºÎ¸¦ Á¦¿ÜÇÑ ·ÎÄÏ º»Ã¼¿¡ ´ëÇÑ ÃÑÁß·®ÀÇ ºñÀ²,ÃßÁø¾à ÃæÀüÀ²)
  • payout ratio
    ¹è´ç ¼ºÇâ
  • priceearnings ratio
    ÁÖ°¡ ¼öÀÍ·ü 9
  • ratio
    ºñ;ºñÀ²
  • respiratory quotient (ratio)
    È£Èí·ü;È£Èíºñ(³»¹ñ´Â ź»ê°¡½ºÀÇ ¾ç°ú ¿ÜºÎ·ÎºÎÅÍ Èí¼öÇÏ´Â »ê¼Ò·®°úÀÇ ºñ)
  • risk-benefit ratio
    À§Ç輺°ú ¼öÀͼº°úÀÇ ºñÀ²
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á